Insider transactions

EDGAR

Fulcrum Therapeutics, Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-20.

Open-market purchases (code P)
6 transactions, 417,562 shares
Sum of shares × price per share: 1,485,742.64
Open-market sales (code S)
8 transactions, 4,241,591 shares
Sum of shares × price per share: 58,989,269.76

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–27 of 27

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-07-17 Filed 2026-07-20TANG KEVIN 10% ownerTANG CAPITAL MANAGEMENT LLC 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)50,9453.52
179,326.4

Derived: shares × price per share. Exact value 179326.40.

7,080,945Indirect (I) See FootnoteNo
F3, F2
  • F3 These shares were purchased in multiple transactions at prices ranging from $3.46 to $3.55.
  • F2 Tang Capital Partners, LP (TCP) beneficially owns 1,668,554 shares, Tang Capital Partners International, LP (TCPI) beneficially owns 2,212,803 shares, Tang Capital Partners III, Inc. (TCP III) beneficially owns 1,668,539 shares, and Tang Capital Partners IV, Inc. (TCP IV) beneficially owns 1,531,049 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV.
Open filing 0001178579-26-000016 Read from the filing’s XML Dispute this row
2026-07-16 Filed 2026-07-20TANG KEVIN 10% ownerTANG CAPITAL MANAGEMENT LLC 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)116,6713.56
415,348.76

Derived: shares × price per share. Exact value 415348.76.

7,030,000Indirect (I) See FootnoteNo
F1, F2
  • F1 The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $3.50 to $3.60. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3.
  • F2 Tang Capital Partners, LP (TCP) beneficially owns 1,668,554 shares, Tang Capital Partners International, LP (TCPI) beneficially owns 2,212,803 shares, Tang Capital Partners III, Inc. (TCP III) beneficially owns 1,668,539 shares, and Tang Capital Partners IV, Inc. (TCP IV) beneficially owns 1,531,049 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV.
Open filing 0001178579-26-000016 Read from the filing’s XML Dispute this row
2026-07-15 Filed 2026-07-15TANG KEVIN 10% ownerTANG CAPITAL MANAGEMENT LLC 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)107,3773.56
382,262.12

Derived: shares × price per share. Exact value 382262.12.

6,913,329Indirect (I) See FootnoteNo
F5, F2
  • F5 These shares were purchased in multiple transactions at prices ranging from $3.50 to $3.60.
  • F2 Tang Capital Partners, LP (TCP) beneficially owns 1,630,142 shares, Tang Capital Partners International, LP (TCPI) beneficially owns 2,160,423 shares, Tang Capital Partners III, Inc. (TCP III) beneficially owns 1,630,127 shares, and Tang Capital Partners IV, Inc. (TCP IV) beneficially owns 1,492,637 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV.
Open filing 0001178579-26-000014 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-15TANG KEVIN 10% ownerTANG CAPITAL MANAGEMENT LLC 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)53,6513.56
190,997.56

Derived: shares × price per share. Exact value 190997.56.

6,730,000Indirect (I) See FootnoteNo
F3, F2
  • F3 These shares were purchased in multiple transactions at prices ranging from $3.54 to $3.60.
  • F2 Tang Capital Partners, LP (TCP) beneficially owns 1,630,142 shares, Tang Capital Partners International, LP (TCPI) beneficially owns 2,160,423 shares, Tang Capital Partners III, Inc. (TCP III) beneficially owns 1,630,127 shares, and Tang Capital Partners IV, Inc. (TCP IV) beneficially owns 1,492,637 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV.
Open filing 0001178579-26-000014 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-15TANG KEVIN 10% ownerTANG CAPITAL MANAGEMENT LLC 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)75,9523.58
271,908.16

Derived: shares × price per share. Exact value 271908.16.

6,805,952Indirect (I) See FootnoteNo
F4, F2
  • F4 These shares were purchased in multiple transactions at prices ranging from $3.53 to $3.60.
  • F2 Tang Capital Partners, LP (TCP) beneficially owns 1,630,142 shares, Tang Capital Partners International, LP (TCPI) beneficially owns 2,160,423 shares, Tang Capital Partners III, Inc. (TCP III) beneficially owns 1,630,127 shares, and Tang Capital Partners IV, Inc. (TCP IV) beneficially owns 1,492,637 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV.
Open filing 0001178579-26-000014 Read from the filing’s XML Dispute this row
2026-07-13 Filed 2026-07-15TANG KEVIN 10% ownerTANG CAPITAL MANAGEMENT LLC 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)12,9663.54
45,899.64

Derived: shares × price per share. Exact value 45899.64.

6,676,349Indirect (I) See FootnoteNo
F1, F2
  • F1 The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $3.54 to $3.55. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3 through 5.
  • F2 Tang Capital Partners, LP (TCP) beneficially owns 1,630,142 shares, Tang Capital Partners International, LP (TCPI) beneficially owns 2,160,423 shares, Tang Capital Partners III, Inc. (TCP III) beneficially owns 1,630,127 shares, and Tang Capital Partners IV, Inc. (TCP IV) beneficially owns 1,492,637 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV.
Open filing 0001178579-26-000014 Read from the filing’s XML Dispute this row
2026-06-30 Filed 2026-07-02Hill Colin Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (32,000) — exercise price 3.66
Acquired (A)32,0000.00
0

Derived: shares × price per share. Exact value 0.00.

32,000Direct (D) No
F1
  • F1 This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.
Open filing 0001193125-26-294683 Read from the filing’s XML Dispute this row
2026-06-30 Filed 2026-07-02Ezekowitz Alan Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (32,000) — exercise price 3.66
Acquired (A)32,0000.00
0

Derived: shares × price per share. Exact value 0.00.

32,000Direct (D) No
F1
  • F1 This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.
Open filing 0001193125-26-294680 Read from the filing’s XML Dispute this row
2026-06-30 Filed 2026-07-02GERAGHTY JAMES A Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (32,000) — exercise price 3.66
Acquired (A)32,0000.00
0

Derived: shares × price per share. Exact value 0.00.

32,000Direct (D) No
F1
  • F1 This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.
Open filing 0001193125-26-294690 Read from the filing’s XML Dispute this row
2026-06-30 Filed 2026-07-02King Rachel K. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (32,000) — exercise price 3.66
Acquired (A)32,0000.00
0

Derived: shares × price per share. Exact value 0.00.

32,000Direct (D) No
F1
  • F1 This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.
Open filing 0001193125-26-294691 Read from the filing’s XML Dispute this row
2026-06-30 Filed 2026-07-02Dorton Katina Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (32,000) — exercise price 3.66
Acquired (A)32,0000.00
0

Derived: shares × price per share. Exact value 0.00.

32,000Direct (D) No
F1
  • F1 This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.
Open filing 0001193125-26-294699 Read from the filing’s XML Dispute this row
2026-06-30 Filed 2026-07-02Gould Robert J Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (32,000) — exercise price 3.66
Acquired (A)32,0000.00
0

Derived: shares × price per share. Exact value 0.00.

32,000Direct (D) No
F1
  • F1 This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.
Open filing 0001193125-26-294697 Read from the filing’s XML Dispute this row
2026-06-30 Filed 2026-07-02Banks Sonja Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (32,000) — exercise price 3.66
Acquired (A)32,0000.00
0

Derived: shares × price per share. Exact value 0.00.

32,000Direct (D) No
F1
  • F1 This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.
Open filing 0001193125-26-294703 Read from the filing’s XML Dispute this row
2026-06-30 Filed 2026-07-02Haviland Kate Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (32,000) — exercise price 3.66
Acquired (A)32,0000.00
0

Derived: shares × price per share. Exact value 0.00.

32,000Direct (D) No
F1
  • F1 This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.
Open filing 0001193125-26-294692 Read from the filing’s XML Dispute this row
2026-06-26 Filed 2026-06-30Ezekowitz Alan Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)18,0003.6452
65,613.6

Derived: shares × price per share. Exact value 65613.6000.

10,927Direct (D) No
F1, F2
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 27, 2026.
  • F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.555 to $3.82, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Open filing 0001193125-26-290622 Read from the filing’s XML Dispute this row
2026-04-23 Filed 2026-05-01Lehrer-Graiwer Joshua Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (64,000) — exercise price 8.08
Acquired (A)64,0000.00
0

Derived: shares × price per share. Exact value 0.00.

64,000Direct (D) No
F1
  • F1 This option was granted on April 23, 2026 and is scheduled to vest in equal monthly installments until April 23, 2029, subject to continued service.
Open filing 0001193125-26-201468 Read from the filing’s XML Dispute this row
2026-02-02 Filed 2026-02-04Gould Robert J Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)15,00010.7238
160,857

Derived: shares × price per share. Exact value 160857.0000.

454,864Direct (D) No
F1, F2
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2025.
  • F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.48 to $11.10, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Open filing 0001193125-26-037573 Read from the filing’s XML Dispute this row
2026-02-02 Filed 2026-02-04Sapir Alex Director · Officer: See Remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock option - Right to Buy — underlying Common Stock (650,000) — exercise price 10.72
Acquired (A)650,0000.00
0

Derived: shares × price per share. Exact value 0.00.

650,000Direct (D) No
F1
  • F1 This option was granted on February 2, 2026 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2026, subject to the reporting person's continued service on each such vesting date.
Open filing 0001193125-26-037572 Read from the filing’s XML Dispute this row
2026-02-02 Filed 2026-02-04Tourangeau Greg Officer: Principal Accounting Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (57,000) — exercise price 10.72
Acquired (A)57,0000.00
0

Derived: shares × price per share. Exact value 0.00.

57,000Direct (D) No
F1
  • F1 This option was granted on February 2, 2026 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2026, subject to the reporting person's continued service on each such vesting date.
Open filing 0001193125-26-037575 Read from the filing’s XML Dispute this row
2026-02-02 Filed 2026-02-04Oltmans Curtis Gale Officer: Chief Legal Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (170,000) — exercise price 10.72
Acquired (A)170,0000.00
0

Derived: shares × price per share. Exact value 0.00.

170,000Direct (D) No
F1
  • F1 This option was granted on February 2, 2026 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2026, subject to the reporting person's continued service on each such vesting date.
Open filing 0001193125-26-037576 Read from the filing’s XML Dispute this row
2026-02-02 Filed 2026-02-04Musso Alan A Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (170,000) — exercise price 10.72
Acquired (A)170,0000.00
0

Derived: shares × price per share. Exact value 0.00.

170,000Direct (D) No
F1
  • F1 This option was granted on February 2, 2026 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2026, subject to the reporting person's continued service on each such vesting date.
Open filing 0001193125-26-037574 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-02-04Gould Robert J Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)15,00010.8726
163,089

Derived: shares × price per share. Exact value 163089.0000.

469,864Direct (D) No
F1, F2
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2025.
  • F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.60 to $11.33, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. This Form 4/A corrects the weighted average price indicated in the Form 4 submitted on January 6, 2026 from $11.8726 to $10.8726.
Open filing 0001193125-26-037606 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-06Gould Robert J Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)15,00011.8726
178,089

Derived: shares × price per share. Exact value 178089.0000.

469,864Direct (D) No
F1, F2
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2025.
  • F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.60 to $11.33, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Open filing 0001193125-26-004572 Read from the filing’s XML Dispute this row
2025-12-15 Filed 2025-12-17Oltmans Curtis Gale Officer: Chief Legal Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)3,45212.92
44,599.84

Derived: shares × price per share. Exact value 44599.84.

10,252Direct (D) No
F1, F2
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025.
  • F2 Includes 10,252 shares that were previously acquired under the Issuer's employee stock purchase plan.
Open filing 0001193125-25-322740 Read from the filing’s XML Dispute this row
2025-12-08 Filed 2025-12-10RA CAPITAL MANAGEMENT, L.P. 10% ownerRA Capital Healthcare Fund LP 10% ownerKolchinsky Peter 10% ownerShah Rajeev M. 10% owner
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,377,02013.33
18,355,676.6

Derived: shares × price per share. Exact value 18355676.60.

8,852,079Indirect (I) See footnotesNo
F1, F2, F3
  • F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.81 to $13.8099 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-25-000596 Read from the filing’s XML Dispute this row
2025-12-08 Filed 2025-12-10RA CAPITAL MANAGEMENT, L.P. 10% ownerRA Capital Healthcare Fund LP 10% ownerKolchinsky Peter 10% ownerShah Rajeev M. 10% owner
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2,706,39714.28
38,647,349.16

Derived: shares × price per share. Exact value 38647349.16.

6,145,682Indirect (I) See footnotesNo
F4, F2, F3
  • F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.81 to $14.805 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-25-000596 Read from the filing’s XML Dispute this row
2025-12-08 Filed 2025-12-10RA CAPITAL MANAGEMENT, L.P. 10% ownerRA Capital Healthcare Fund LP 10% ownerKolchinsky Peter 10% ownerShah Rajeev M. 10% owner
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)91,72214.98
1,373,995.56

Derived: shares × price per share. Exact value 1373995.56.

6,053,960Indirect (I) See footnotesNo
F5, F2, F3
  • F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.81 to $15.39 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-25-000596 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

No Form 13F position in this issuer is placed in the store. A holder not yet linked or not yet filed is absent, not zero.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
EcoR1 Capital, LLC Common Stock8.96,803,78509/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0000935836-26-000588 Dispute this row
Oleg Nodelman Common Stock8.96,803,78509/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0000935836-26-000588 Dispute this row
EcoR1 Capital Fund Qualified, L.P. Common Stock8.26,297,53809/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0000935836-26-000588 Dispute this row
ADAR1 Capital Management, LLC Common Stock, par value $0.001 per share8.76,648,027.0009/30/2026 Filed 2026-11-16SCHEDULE 13GOpen filing 0001104659-26-128728 Dispute this row
Daniel Schneeberger Common Stock, par value $0.001 per share8.76,648,027.0009/30/2026 Filed 2026-11-16SCHEDULE 13GOpen filing 0001104659-26-128728 Dispute this row
Nantahala Capital Management, LLC Common stock, par value $0.001 per share8.626,575,352.0009/30/2026 Filed 2026-11-13SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-127211 Dispute this row
Wilmot B. Harkey Common stock, par value $0.001 per share8.626,575,352.0009/30/2026 Filed 2026-11-13SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-127211 Dispute this row
Daniel Mack Common stock, par value $0.001 per share8.626,575,352.0009/30/2026 Filed 2026-11-13SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-127211 Dispute this row
Montanova Capital, LLC Common Stock, par value $0.001 per share00.0009/30/2026 Filed 2026-11-13SCHEDULE 13G/AAmendment 3Open filing 0000919574-26-007765 Dispute this row
Averill Master Fund, Ltd. Common Stock, par value $0.001 per share00.0009/30/2026 Filed 2026-11-13SCHEDULE 13G/AAmendment 3Open filing 0000919574-26-007765 Dispute this row
Aaron Cowen Common Stock, par value $0.001 per share00.0009/30/2026 Filed 2026-11-13SCHEDULE 13G/AAmendment 3Open filing 0000919574-26-007765 Dispute this row
BANK OF AMERICA CORP /DE/ Common Stock1.51,114,867.0009/30/2026 Filed 2026-10-28SCHEDULE 13G/AAmendment 1Open filing 0000070858-26-000532 Dispute this row
BlackRock Portfolio Management LLC Common Stock8.16,155,43709/30/2026 Filed 2026-10-27SCHEDULE 13G/AAmendment 1Open filing 0002052113-26-001118 Dispute this row
TANG CAPITAL MANAGEMENT, LLC Common stock, par value $0.001 per share10.46,913,329.0007/13/2026 Filed 2026-07-15SCHEDULE 13G/AAmendment 1Open filing 0001214659-26-008613 Dispute this row
KEVIN TANG Common stock, par value $0.001 per share10.46,913,329.0007/13/2026 Filed 2026-07-15SCHEDULE 13G/AAmendment 1Open filing 0001214659-26-008613 Dispute this row
TANG CAPITAL PARTNERS, LP Common stock, par value $0.001 per share2.51,630,142.0007/13/2026 Filed 2026-07-15SCHEDULE 13G/AAmendment 1Open filing 0001214659-26-008613 Dispute this row
TANG CAPITAL PARTNERS INTERNATIONAL, LP Common stock, par value $0.001 per share3.22,160,423.0007/13/2026 Filed 2026-07-15SCHEDULE 13G/AAmendment 1Open filing 0001214659-26-008613 Dispute this row
TANG CAPITAL PARTNERS III, INC Common stock, par value $0.001 per share2.51,630,127.0007/13/2026 Filed 2026-07-15SCHEDULE 13G/AAmendment 1Open filing 0001214659-26-008613 Dispute this row
TANG CAPITAL PARTNERS IV, INC Common stock, par value $0.001 per share2.21,492,637.0007/13/2026 Filed 2026-07-15SCHEDULE 13G/AAmendment 1Open filing 0001214659-26-008613 Dispute this row
TCG Crossover GP II, LLC Common Stock, par value $0.001 per share0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0001193125-26-352345 Dispute this row
TCG Crossover Fund II, L.P. Common Stock, par value $0.001 per share0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0001193125-26-352345 Dispute this row
Chen Yu Common Stock, par value $0.001 per share0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0001193125-26-352345 Dispute this row
RA Capital Management, L.P. Common Stock, $0.001 par value per share0.00.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 7Open filing 0001231919-26-000923 Dispute this row
Peter Kolchinsky Common Stock, $0.001 par value per share0.00.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 7Open filing 0001231919-26-000923 Dispute this row
Rajeev Shah Common Stock, $0.001 par value per share0.00.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 7Open filing 0001231919-26-000923 Dispute this row
RA Capital Healthcare Fund, L.P. Common Stock, $0.001 par value per share0.00.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 7Open filing 0001231919-26-000923 Dispute this row
Nantahala Capital Management, LLC Common stock, par value $0.001 per share8.225,475,040.0006/30/2026 Filed 2026-08-14SCHEDULE 13GOpen filing 0001104659-26-097278 Dispute this row
Wilmot B. Harkey Common stock, par value $0.001 per share8.225,475,040.0006/30/2026 Filed 2026-08-14SCHEDULE 13GOpen filing 0001104659-26-097278 Dispute this row
Daniel Mack Common stock, par value $0.001 per share8.225,475,040.0006/30/2026 Filed 2026-08-14SCHEDULE 13GOpen filing 0001104659-26-097278 Dispute this row
Montanova Capital, LLC Common Stock, par value $0.001 per share5.53,680,921.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0000919574-26-005528 Dispute this row
Averill Master Fund, Ltd. Common Stock, par value $0.001 per share3.82,553,201.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0000919574-26-005528 Dispute this row
Aaron Cowen Common Stock, par value $0.001 per share5.53,680,921.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0000919574-26-005528 Dispute this row
BANK OF AMERICA CORP /DE/ Common Stock6.74,468,123.0006/30/2026 Filed 2026-08-03SCHEDULE 13GOpen filing 0000070858-26-000396 Dispute this row
BlackRock, Inc. Common Stock7.24,802,88006/30/2026 Filed 2026-07-28SCHEDULE 13G/AAmendment 4Open filing 0002012383-26-002576 Dispute this row
BlackRock Portfolio Management LLC Common Stock6.04,021,37906/30/2026 Filed 2026-07-17SCHEDULE 13GOpen filing 0002052113-26-000745 Dispute this row
EcoR1 Capital, LLC Common Stock9.06,000,000.0006/17/2026 Filed 2026-06-25SCHEDULE 13GOpen filing 0000935836-26-000330 Dispute this row
Oleg Nodelman Common Stock9.06,000,000.0006/17/2026 Filed 2026-06-25SCHEDULE 13GOpen filing 0000935836-26-000330 Dispute this row
EcoR1 Capital Fund Qualified, L.P. Common Stock8.45,614,199.0006/17/2026 Filed 2026-06-25SCHEDULE 13GOpen filing 0000935836-26-000330 Dispute this row
EcoR1 Capital, LLC Common Stock9.06,000,000.0006/17/2026 Filed 2026-06-25SCHEDULE 13GOpen filing 0000935836-26-000331 Dispute this row
Oleg Nodelman Common Stock9.06,000,000.0006/17/2026 Filed 2026-06-25SCHEDULE 13GOpen filing 0000935836-26-000331 Dispute this row
EcoR1 Capital Fund Qualified, L.P. Common Stock8.45,614,199.0006/17/2026 Filed 2026-06-25SCHEDULE 13GOpen filing 0000935836-26-000331 Dispute this row
TANG CAPITAL MANAGEMENT, LLC Common stock, par value $0.001 per share8.25,451,800.0006/03/2026 Filed 2026-06-10SCHEDULE 13GOpen filing 0001214659-26-007338 Dispute this row
KEVIN TANG Common stock, par value $0.001 per share8.25,451,800.0006/03/2026 Filed 2026-06-10SCHEDULE 13GOpen filing 0001214659-26-007338 Dispute this row
TANG CAPITAL PARTNERS, LP Common stock, par value $0.001 per share1.91,249,373.0006/03/2026 Filed 2026-06-10SCHEDULE 13GOpen filing 0001214659-26-007338 Dispute this row
TANG CAPITAL PARTNERS INTERNATIONAL, LP Common stock, par value $0.001 per share2.51,703,690.0006/03/2026 Filed 2026-06-10SCHEDULE 13GOpen filing 0001214659-26-007338 Dispute this row
TANG CAPITAL PARTNERS III, INC Common stock, par value $0.001 per share1.91,249,367.0006/03/2026 Filed 2026-06-10SCHEDULE 13GOpen filing 0001214659-26-007338 Dispute this row
TANG CAPITAL PARTNERS IV, INC Common stock, par value $0.001 per share1.91,249,370.0006/03/2026 Filed 2026-06-10SCHEDULE 13GOpen filing 0001214659-26-007338 Dispute this row
Nantahala Capital Management, LLC Common stock, par value $0.001 per share4.583,050,040.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-062675 Dispute this row
Wilmot B. Harkey Common stock, par value $0.001 per share4.583,050,040.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-062675 Dispute this row
Daniel Mack Common stock, par value $0.001 per share4.583,050,040.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-062675 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,638,030 filings read, dated 2004-06-14 to 2026-11-19: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
201555,117
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,123

Filings made before the SEC required XML are listed, not extracted.

Back to Fulcrum Therapeutics, Inc.